4-(N⁹-adenin)-methylbutanoate | 326797-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 4-(N⁹-adenin)-methylbutanoate
• 英文别名: methyl-5-(9-adenenyl)-pentanoate；5-(6-Amino-purin-9-yl)-pentanoic acid methyl ester；methyl 5-(6-aminopurin-9-yl)pentanoate
• CAS: 326797-58-4
• 化学式: C₁₁H₁₅N₅O₂
• 分子量: 249.272
• InChiKey: OEEPTEXSTWRKQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  95.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(N⁹-adenin)-methylbutanoate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 N⁹-(δ-hydroxycarbonyl-n-butyl)adenine
  参考文献：
  名称：

  基于异羟肟酸酯的腺苷酸环化酶抑制剂。第1部分：无环接头对P位点结合的影响。

  摘要：

  腺苷酸环化酶（AC）是一类酶，由于其将ATP转化为cAMP的能力而成为信号转导的关键元素。这种转化的催化机制是通过ATP与嘌呤结合位点（P-位点）的初始结合而进行的，随后是金属介导的环化反应而失去了焦磷酸盐。用已知抑制剂对AC进行的晶体学分析表明，活性位点中存在两种金属。目前，已知腺苷酸环化酶的九种同工型，并且以组织特异性的方式表达独特的同工型组合。腺苷酸环化酶同工型特异性抑制剂的开发可能被证明是设计新型治疗剂的有用策略。为了开发新型AC抑制剂，我们选择了一种利用腺嘌呤环系统分子通过柔性无环接头与金属配位异羟肟酸连接的设计方法。对设计的抑制剂针对V AC型进行分析，其中接头的大小和杂原子含量发生变化，以探测酶中核苷酸和金属结合位点的相互作用。

  DOI：

  10.1016/s0960-894x(02)00653-4
• 作为产物：
  描述：

  9-(4-氯丁基)嘌呤-6-胺 在 盐酸 作用下， 以 水 为溶剂， 反应 22.0h， 生成 4-(N⁹-adenin)-methylbutanoate
  参考文献：
  名称：

  Pini; Rossi; Cornaglia Ferraris, Bollettino Chimico Farmaceutico, 2000, vol. 139, # 3, p. 107 - 113

  摘要：

  DOI：

文献信息

• Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
  申请人：Vatner F. Stephen

  公开号：US20060252774A1

  公开（公告）日：2006-11-09

  The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss therefrom, as well as treatment for cardiac conditions and diseases including conditions characterized by abnormal heart rate.

  这项发明涉及含有一种或多种能够有效调节第5型腺苷酸环化酶活性的化合物的药物组合物，以及治疗神经系统疾病和障碍、以及由此引起的运动功能丧失的方法，以及用于治疗心脏疾病和疾病的方法，包括以异常心率为特征的情况。
• Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
  申请人：——

  公开号：US20020068745A1

  公开（公告）日：2002-06-06

  The present invention relates to derivatives and analogues of adenine, which inhibit adenylyl cyclase activity. The present invention also relates to a method of preventing and inhibiting a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amount of a compound according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a patient's fibroproliferative vasculopathy such as chronic allograft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of adenylyl cyclase activity and a method for treating congestive heart failure.

  本发明涉及腺嘌呤的衍生物和类似物，其抑制腺苷酸环化酶活性。本发明还涉及一种预防和抑制患者血管损伤后纤维增殖性血管病的方法，或血管手术后的方法，包括向患者施用根据本发明的化合物的有效量，即在血管损伤后或血管手术后的一到两周内，有效地治疗或预防患者的纤维增殖性血管病，如慢性移植物排斥或血管创伤后的血管再狭窄。本发明还涉及一种测量腺苷酸环化酶活性抑制的方法和一种治疗充血性心力衰竭的方法。
• US6887880B2
  申请人：——

  公开号：US6887880B2

  公开（公告）日：2005-05-03
• [EN] ADENINE BASED INHIBITORS OF ADENYLYL CYCLASE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF<br/>[FR] INHIBITEURS D'ADENYLYLE CYCLASE A BASE D'ADENINE, COMPOSITIONS PHARMACEUTIQUES ET PROCEDE D'UTILISATION
  申请人：COR THERAPEUTICS INC

  公开号：WO2002040481A2

  公开（公告）日：2002-05-23

  The present invention relates to derivatives and analogues of adenine, which inhibit adenylyl cyclase activity. The present invention also relates to a method of preventing and inhibiting a patient's fibroporliferative vasculopathy following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amount of a compound according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a patient's fibroproliferative vasculopathy such as chronic allorgraft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of adenylyl cyclase activity and a method for treating congestive heart failure.
• Pini; Rossi; Cornaglia Ferraris, Bollettino Chimico Farmaceutico, 2000, vol. 139, # 3, p. 107 - 113
  作者：Pini、Rossi、Cornaglia Ferraris、Stradi

  DOI：——

  日期：——